|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection显示文摘AIM: To determine the efficacy of our therapeutic strategy for Helicobacter pylori (H. pylori) eradication and to identify predictive factors for successful eradication. METHODS: From April 2006 to June 2010, we retrospectively assessed 2428 consecutive patients (1025 men, 1403 women; mean age 55 years, age range 18-92 years) with gastric histology positive for H. pylori infection referred to our unit for 13-C urea breath test(UBT), after first-line therapy with proton pump inhibitor (PPI) b.i.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 d. Patients who were still positive to UBT were recommended a second-line therapy (PPI b.i.d. + amoxicillin 1 g b.i.d. + tinidazole 500 mg b.i.d. for 14 d). Third choice treatment was empirical with PPI b.i.d. + amoxicillin 1 g b.i.d. + levofloxacin 250 mg b.i.d. for 14 d. RESULTS: Out of 614 patients, still H. pylori-positive after first-line therapy, only 326 and 19 patients respectively rechecked their H. pylori status by UBT after the suggested second and third-line regimens. 'Per protocol' eradication rates for first, second and thirdline therapy were 74.7% (95% CI: 72.7%-76.4%), 85.3% (95% CI: 81.1%-89.1%) and 89.5% (95% CI: 74.9%-103%) respectively. The overall percentage of patients with H. pylori eradicated after two treatments was 97.8% (95% CI: 97.1%-98.4%), vs 99.9% (95% CI: 99.8%-100%) after three treatments. The study found that eradication therapy was most effective in patients with ulcer disease (P < 0.05, P = 0.028), especially in those with duodenal ulcer. Smoking habits did not significantly affect the eradication rate. CONCLUSION: First-line therapy with amoxicillin and clarithromycin produces an H. pylori eradication rate comparable or superior to other studies and secondline treatment can still be triple therapy with amoxicillin and tinidazole. | Giuliana Sereni Francesco Azzolini Lorenzo Camellini Debora Formisano Francesco Decembrino Veronica Iori Cristiana Tioli Maurizio Cavina Francesco Di Mario Giuliano Bedogni Romano Sassatelli | 2012 | World Journal of Gastroenterology2012，18，33： | 4 |
| 2 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa, ZD1839) in non-small-cell lung cancer显示文摘 | Parra HS Cavina R Latteri F | 2004 | Br J Cancer2004，91，2： | 1 |
| 3 | Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epicermal growth factor receptor in refractory non-small-cell lung cancer显示文摘 | Santoro A Cavina R Latteri F | 2004 | Ann Oncol2004，15，1： | 1 |
| 4 | Conc-urrent radiotherapy and weekly paclitmxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix, a pilot study with intensification of dose 显示文摘 | CERROTTA A GARDAN G CAVINA R | 2002 | I Eur J Gynaeeol Oncol2002，23，2： | 1 |
| 5 | Is that within reach? fMRI reveals that the human superior parieto -occip- ital cortex encodes obj eets reachable by the hand显示文摘 | Gallivan J P Cavina -Pratesi C Culham J C | 2009 | The Journal of Neuroscience2009，29，： | 1 |
| 6 | Analysis of epider- mal growth factor receptor expreession as a predictive factor for response to getltinib (' Iressa ', ZD1839) in non-small cell lung cancer显示文摘 | PARRA HS CAVINA R LATFEI F | 2004 | Br J Caner2004，91，2： | 1 |
| 7 | Superiority of three week vs four week schedule of cisplatin (CDDP) and gemcitabine(GEM):results of a randomized phase Ⅱ study显示文摘 | Soto Parra HJ Cavina R Antonelli G | 2000 | Lung Cancer2000，29，1： | 1 |
| 8 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa',ZD1839) in non-small-ceil lung cancer显示文摘 | PARRA HS CAVINA R LATFERI F | 2004 | Br J Cancer2004，91，2： | 1 |
| 9 | Superiority of three week vs four week schedule of cisplatin (CDDP) and gemcitabine(GEM):results of a randomized phase Ⅱ study显示文摘 | Soto Parra HJ Cavina R Antonelli G | 2000 | Lung Cancer2000，29，1： | 1 |
| 10 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib in non-small-cell lung Cancer显示文摘 | Parra HS Cavina R Latteri F | 2004 | Br J Cancer2004，91，2： | 1 |
| 11 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib('Iressa', ZD1839)in non-small-cell lung cancer 显示文摘 | Parra HS Cavina R Latteri F | 2004 | BrJ Cancer2004，91，2： | 1 |
| 12 | Activity of a specific inhibitor,gefitinib (Iressa,ZD1839),of epidermal growth factor receptor in refractory non-small-cell lung cancer显示文摘 | Santoro A Cavina R Latteri F | 2004 | Arm Oncol2004，15，1： | 1 |
| 13 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib('Iressa',ZD 1839)in non-small cell lung cancer显示文摘 | Parra HS Cavina R Latteri F | 2004 | Br J Cancer2004，91，2： | 1 |
| 14 | Superiority of three weeks vs four weeks schedule of cisplatin (CDDP) and gemcitabine ( GEM ) : results of a randomized phase Ⅱ study显示文摘 | Sotoparra HJ Cavina R Antonelli G | 2000 | Lung Cancer2000，29，1： | 1 |
| 15 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa',ZD1839) in non-small-cell lung cancer显示文摘 | Parra HS Cavina R Latteri F | 2004 | Br J Cancer2004，91，2： | 1 |
| 16 | Pemetrexed single agent in previously treated non small cell lung cancer:a multi-institutional observational study显示文摘 | Berza A Garassino I Cavina R | 2008 | Lung Cancer2008，60，： | 1 |
| 17 | Superiority of there week vs four week schedule of cisplatin (CDDP) and gemcitabine(GEM) : Result s of a randomized phase Ⅱ study显示文摘 | Soto-Parra HJ Cavina R Antonelli G | 2000 | Lung Cancer2000，29，1： | 1 |
| 18 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 显示文摘 | Parra H S Cavina R Latteri F | 2004 | Br J Cancer2004，91，2： | 1 |
| 19 | Pemetrexed single agent in previously treated non-small cell lung cancer:a multi-institutional observational study显示文摘 | Bearz A Garassino I Cavina R | 2008 | Lung Cancer2008，60，2： | 1 |
| 20 | Three -week versus four week schedule of cisplatin and gemcitabine: results of a randomized phase Ⅱ study 显示文摘 | Soto Parra H Cavina R Latteri F | 2002 | Ann 0ncol2002，13，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员